Insulin-dependent diabetes is
a significant illness in developed countries and
is fast emerging as a major illness in developing
areas of the world. Traditional treatments require
a daily regime of invasive injection treatments.
The aim of this research is to develop a non-invasive
treatment for insulin - dependent diabetes (IDD).
WABRI is developing a small, non-protein molecule
that mimics insulin but, unlike insulin, is suitable
for oral delivery. To date, a group of molecules
that acts in a similar fashion to insulin has
been identified (insulin mimetics). In a recent
animal trial, the most promising mimetic was able
to lower blood glucose in diabetic mice. Compounds
that stimulate the insulin receptor for diabetes
treatment can also lead the research into compounds
that shut-down the insulin-like growth factor
receptor, a receptor with a known role in certain
cancers, including prostate cancer.
New treatments for diabetes and cancer will have
major benefits to individuals suffering from these
diseases.
Molecular model of insulin
|
Rotate L-mouse
/ Menu R-mouse |
Contact Details of Program Leader
Name: A/Prof Erik Helmerhorst
Institution: WABRI - Curtin University
Ph: +61 8 9266 7378
Fax: +61 8 9266 2342
Email:
|
